Combination therapy for cardiac amyloidosis
Part of Blood & lymphatic, Heart & circulation clinical trials.
This trial tests a three-drug combination (selinexor, daratumumab, and dexamethasone) for people with a specific type of amyloidosis that affects the heart. The goal is to see if this treatment can help reduce the abnormal proteins causing the disease and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- A confirmed diagnosis of light-chain (AL) amyloidosis with heart involvement.
- Your disease must be at a certain stage (Mayo stage IIIa or IIIb), which indicates more advanced heart-related symptoms.
- You need to have measurable levels of abnormal proteins in your blood or urine.
- You must not be pregnant or breastfeeding, and agree to use contraception if applicable.
- You must be willing to sign an informed consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy, CAR-NK, for people with amyloidosis that has affected their heart and hasn't responded well to initial treatments. The goal is to see if the therapy can help control the disease and improve heart function.
This trial tests a combination of three drugs — daratumumab, pomalidomide, and dexamethasone — for people newly diagnosed with AL amyloidosis. The goal is to see if this treatment helps reduce the abnormal proteins and improve organ function.
This trial studies whether ultrasound therapy can help people with amyloidosis that affects the heart. It’s aimed at improving heart-related outcomes in AL or transthyretin (ATTR) cardiac amyloidosis.
This trial tests a new drug combination for people with a specific type of AL amyloidosis (light chain amyloidosis) that has a genetic marker called t(11;14). The treatment includes Sonrotoclax (a targeted therapy) plus steroids, and possibly another drug called daratumumab, to see if it can help control the disease.
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
Hear when a new Light-chain Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.